In vivo effects of rosiglitazone in a human neuroblastoma xenograft

被引：26

作者：

Cellai, I. ^{[1
]}

Petrangolini, G. ^{[2
]}

Tortoreto, M. ^{[2
]}

Pratesi, G. ^{[2
]}

Luciani, P. ^{[1
]}

Deledda, C. ^{[1
]}

Benvenuti, S. ^{[1
]}

Ricordati, C. ^{[3
]}

Gelmini, S. ^{[4
]}

Ceni, E. ^{[5
]}

Galli, A. ^{[5
]}

Balzi, M. ^{[6
]}

Faraoni, P. ^{[6
]}

Serio, M. ^{[1
]}

Peri, A. ^{[1
]}

机构：

[1] Univ Florence, Ctr Res Transfer & High Educ Chron Inflammatory D, Dept Clin Physiopathol, Endocrine Unit, I-50139 Florence, Italy

[2] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Labs, I-20133 Milan, Italy

[3] Univ Milan, Sch Vet Med, Sect Vet & Avian Pathol, Dept Vet Pathol Hyg & Publ Hlth, I-20133 Milan, Italy

[4] Univ Florence, Ctr Res Transfer & High Educ Chron Inflammatory D, Dept Clin Physiopathol, Clin Biochem Unit, I-50139 Florence, Italy

[5] Univ Florence, Ctr Res Transfer & High Educ Chron Inflammatory D, Dept Clin Physiopathol, Gastroenterol Unit, I-50139 Florence, Italy

[6] Univ Florence, Ctr Res Transfer & High Educ Chron Inflammatory D, Dept Clin Physiopathol, Radiat Biol Unit, I-50139 Florence, Italy

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 04期

关键词：

PPAR gamma; RGZ; NB; xenograft; ACTIVATED-RECEPTOR-GAMMA; HIGH-RISK NEUROBLASTOMA; HUMAN PROSTATE-CANCER; PPAR-GAMMA; CELL-LINES; LUNG-CANCER; PHASE-II; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); LIGAND TROGLITAZONE; GROWTH-INHIBITION;

D O I：

10.1038/sj.bjc.6605506

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Neuroblastoma (NB) is the most common extra-cranial solid tumour in infants. Unfortunately, most children present with advanced disease and have a poor prognosis. There is in vitro evidence that the peroxisome proliferator-activated receptor gamma (PPAR gamma) might be a target for pharmacological intervention in NB. We have previously demonstrated that the PPAR gamma agonist rosiglitazone (RGZ) exerts strong anti-tumoural effects in the human NB cell line, SK-N-AS. The aim of this study was to evaluate whether RGZ maintains its anti-tumoural effects against SK-N-AS NB cells in vivo. METHODS AND RESULTS: For this purpose, tumour cells were subcutaneously implanted in nude mice, and RGZ (150 mg kg(-1)) was administered by gavage daily for 4 weeks. At the end of treatment, a significant tumour weight inhibition (70%) was observed in RGZ-treated mice compared with control mice. The inhibition of tumour growth was supported by a strong anti-angiogenic activity, as assessed by CD-31 immunostaining in tumour samples. The number of apoptotic cells, as determined by cleaved caspase-3 immunostaining, seemed lower in RGZ-treated animals at the end of the treatment period than in control mice, likely because of the large tumour size observed in the latter group. CONCLUSIONS: To our knowledge, this is the first demonstration that RGZ effectively inhibits tumour growth in a human NB xenograft and our results suggest that PPAR gamma agonists may have a role in anti-tumoural strategies against NB. British Journal of Cancer (2010) 102, 685-692. doi:10.1038/sj.bjc.6605506 www.bjcancer.com Published online 12 January 2010 (C) 2010 Cancer Research UK

引用

页码：685 / 692

页数：8

共 74 条

[61] Adrenocortical adenoma and carcinoma: Histopathological and molecular comparative analysis [J].